The pharmacy supply chain is one of the most complex and opaque parts of the healthcare ecosystem. Co-pay discounts and other rebates may lower costs, but do not address the underlying cost-drivers of the pharmaceutical industry. Steve Wojcik, VP, National Business Group on Health and Caleb Alexander, Co-Director, Johns Hopkins Center for Drug Safety and Effectiveness give their take on how co-pay discounts can have long-term effects on prescription drug pricing.
